Brief: VBI Vaccines Expands Proprietary Technology Platforms With Development Of Novel mRNA-Launched eVLP Vaccine Program
26/10/2023 13:42
Oct 26 (Reuters) - VBI Vaccines Inc VBIV.O :
* VBI VACCINES EXPANDS PROPRIETARY TECHNOLOGY PLATFORMS WITH
DEVELOPMENT OF A NOVEL MRNA-LAUNCHED EVLP VACCINE PROGRAM
* VBI VACCINES - PRECLINICAL DATA SHOWS NOVEL MRNA-LAUNCHED
EVLPS
GENERATE ENHANCED B-CELL AND T-CELL RESPONSES VERSUS
MRNA-EXPRESSION OF ANTIGENS ALONE
* VBI VACCINES - NEW MLE TECHNOLOGY ENABLES MANUFACTURING OF
PARTICULATE VACCINES ON ACCELERATED TIMELINE, SIMILAR TO OTHER
MRNA MANUFACTURING TIMELINES
Source text for Eikon: ID:nBw6zXMhMa
Further company coverage: VBIV.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on VBI Vaccines
See all newsBrief: VBI Vaccines Provides Update On Its Restructuring Proceedings
Brief: Vbi Vaccines Announces New Tumor Response Data From Ongoing Randomized Controlled Phase 2B Study Of Vbi-1901 In Recurrent Glioblastoma Patients
VBI Vaccines Inc reports results for the quarter ended in March - Earnings Summary
Brief: VBI Vaccines Says Entered At Market Offering Deal For Gross Proceeds Of Up To $8.5 Mln
Brief: VBI Vaccines Q1 Adjusted EPS USD -0.55